Almac Group
Almac Group is a privately held, Northern Ireland–headquartered CDMO providing integrated drug development, manufacturing, clinical supply, and precision-medicine/diagnostic services to global biopharma and biotech companies across 18 facilities in Europe, North America, and Asia.
- Company typePrivate
- Founded1970
- HeadquartersCraigavon, United Kingdom
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Almac Group does
Almac Group is a privately held, Northern Ireland–headquartered contract development and manufacturing organization (CDMO) founded in 1970, generating approximately £1.1 billion in annual revenue with 7,900+ employees across 18 facilities in Europe, North America, and Asia. The company provides integrated pharmaceutical and diagnostic services across the full drug development lifecycle, operating seven core business units: Almac Diagnostic Services, API Services & Chemical Development, Pharmaceutical Development, Analytical & Solid State Services, Clinical Services, Almac Clinical Technologies, and Commercial Services, plus a wholly owned pharma subsidiary (Galen) and an early-stage drug discovery arm (Almac Discovery). Its customers include top-25 global biopharma and a long tail of biotechs, and Almac states it has contributed to approximately 50% of FDA-approved New Molecular Entities over the past five years and supports 30% of EU approved/pre-registered gene therapy products.
The technology stack spans proprietary software platforms — IXRS3 interactive response technology, WebEZ supply assignment, TempEZ temperature management, Almac One randomization, Almac Trial Coordinator eClinical platform, and the claraT gene expression report — alongside wet-lab capabilities in small molecules, peptides, oligonucleotides, highly potent APIs, biocatalysis (INSIGHT/selectAZyme databases, cGMP flow hydrogenation), and CLIA/CAP/ISO 15189-accredited genomic and companion-diagnostic laboratories. Almac's Northern Ireland base provides unique dual access to EU and UK markets under the Northern Ireland Protocol, and the company holds a uniquely broad regulatory certification stack (CLIA, CAP, ISO 15189, ISO 13485, ISO 17025, EU IVDR, UKCA, FDA 21 CFR Part 820).
Almac monetizes primarily through project-based fee-for-service CDMO contracts and diagnostic service agreements, with revenue generated from API manufacture, formulation development, clinical trial supply and packaging, commercial manufacturing, biomarker and companion-diagnostic development, and IRT/eClinical technology licensing. Go-to-market is direct enterprise sales via regional business development teams (EU, US, APAC) supported by the Almac Gateway client portal, with marketing driven by industry conferences, a knowledge centre, and direct engagement on RFI/RFP processes. Customer concentration is low, with a diversified roster across enterprise pharma and biotech and no disclosed anchor-account dependency.
Almac Group firmographics
Firmographics- Name
- Almac Group
- Legal name
- Almac Group
- Website
- https://almacgroup.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Almac Group is a privately held, Northern Ireland–headquartered CDMO providing integrated drug development, manufacturing, clinical supply, and precision-medicine/diagnostic services to global biopharma and biotech companies across 18 facilities in Europe, North America, and Asia.
- Ownership category
- akta.pro rank
Almac Group industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO) Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
Keywords
Where Almac Group is headquartered
LocationHeadquarters
- HQ city
- Craigavon
- HQ country
- United Kingdom
- HQ region
- Europe
Offices15 records
Markets served
Almac Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: Fee-for-service CDMO model providing integrated pharmaceutical services across the drug development lifecycle, including API manufacture, formulation development, clinical trial supply, and commercial-scale manufacturing. Revenue generated through project-based contracts with biopharmaceutical companies.
- Diagnostic Services: Precision medicine services including genomic services, biomarker development, companion diagnostics, and clinical testing. Revenue from assay development, validation, and testing services.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Almac Group product offering
Product offeringCore offering
Almac Group is a contract development and manufacturing organization (CDMO) providing integrated pharmaceutical services across the entire drug development lifecycle. It offers API development and manufacture, formulation development, clinical trial supply and packaging, commercial-scale manufacturing, and precision medicine companion diagnostics. The company serves global biopharmaceutical and biotechnology companies through seven business units operating from 18 facilities across Europe, North America, and Asia-Pacific.
Product overview
Almac Group is a global pharmaceutical services provider offering a comprehensive, integrated platform across the entire drug development lifecycle. The company operates through seven distinct business units: Almac Diagnostic Services (precision medicine and companion diagnostics), API Services & Chemical Development, Pharmaceutical Development, Analytical & Solid State Services, Clinical Services, Almac Clinical Technologies (IRT and eClinical solutions), and Commercial Services. Key products include the IXRS3 interactive response technology platform, Almac Trial Coordinator eClinical platform, TempEZ temperature management system, WebEZ patient supply assignment system, and the claraT gene expression reporting solution. The company provides end-to-end services from early-phase development through commercial manufacturing and distribution, supported by global laboratories (UK, USA, and Asia Pacific) accredited to CLIA, CAP, ISO 15189, and ISO 13485 standards.
Differentiator
Problem solved
Functional benefit
Brands
- IXRS®3: Interactive Response Technology platform for clinical trial management
- TempEZ
- Almac One
- Almac Trial Coordinator
- claraT
- Almac Adapt
- WebEZ
- NeoPeptides
- Galen
Products and services
- Almac Diagnostic Services Precision medicine division providing genomic services, clinical biomarker and companion diagnostics (CDx) development, and global clinical trial testing from CLIA and CAP accredited laboratories for biopharma and biotech companies.
- API Services & Chemical Development Services for all stages of drug development for small molecules (including highly potent), peptides, and oligonucleotides, including API manufacturing, radiolabelling, biocatalysis, and custom synthesis.
- Pharmaceutical Development Expert development and manufacturing solutions for all phases of clinical trials, including early and late-phase formulation development, bioavailability enhancement, and GMP manufacturing.
- Analytical & Solid State Services Comprehensive solutions to support drug substance (API) and drug product development programs, including method development, release testing, stability testing, and solid state services.
- Clinical Services Global clinical supply chain solution covering clinical trial supply, packaging, labelling, distribution, supply chain solutions, and patient-focused services including direct-to-patient delivery.
- Almac Clinical Technologies Clinical trial technology solutions including IXRS3 interactive response technology, eCOA, eConsent, visit management, biostatistics consulting, and Almac ONE randomization and IRT solutions.
- Commercial Services Commercial manufacturing, packaging, serialization, storage, distribution, and pharmaceutical product launch services for the EU market and globally.
- Almac Trial Coordinator eClinical platform launched as part of a $48M investment to improve clinical trial management through interoperability, standardization, and flexibility to address system fragmentation.
- IXRS3 Interactive Response Technology Interactive Response Technology (IRT) platform for managing key components of clinical trials, with configurable features and IRT boosters including ART (drug accountability), OVERSIGHT (trial data integrity), and DCT support.
- WebEZ Fully validated system for assignment of clinical supplies to patients, providing simple patient management options configurable for various clinical trials.
- TempEZ Fully validated temperature management system for clinical supplies, supporting temperature monitoring and excursion reporting.
- claraT Report Unique gene expression report enabling cancer researchers to discover novel insights within pharmacodynamic biomarker discovery by evaluating multiple biologies in parallel.
- Companion Diagnostics (CDx) Development Service End-to-end CDx development, validation, manufacturing, and commercialization services including CDx development and validation, IVD kit manufacturing, and flexible commercialization models.
- Almac PNPLA3 Genotyping Kit Qualitative qPCR-based kit for identification of I148M (rs738409) genotype within the PNPLA3 gene for MASH/MASLD research.
- Specimen Collection & Logistics Service End-to-end clinical trial specimen collection and logistics service including kit design, manufacturing, labelling, supply chain management, and global distribution.
- Specialty Central Lab Service Premium 'white glove' specialty central lab service for end-to-end sample management including specimen processing, storage, and downstream molecular analysis.
- Almac Discovery Research-driven drug discovery company dedicated to development of novel therapeutics using cutting edge research techniques for first-in-class preclinical stage assets.
- Galen Pharmaceuticals Global pharmaceutical company within Almac Group, developing, marketing, and selling medicines worldwide and partnering with other companies for development and commercialization.
- Almac One Patient randomization and IRT solution for supply chain management, facilitating direct-to-patient distribution models.
- Almac Gateway Client Portal Client portal providing access to online services including My Dashboard, My Clinical Supplies, TempEZ, Label Approval System, Depot Network, and Pharma POP.
Quantifiable outcome
- 50% of all FDA approved New Molecular Entities (NMEs) in the last 5 years
- +3 more outcomes
Companies that use Almac Group
Customer profileNamed customers12 records
Segments3 records
Ideal customer profiles3 records
Almac Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Almac Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- NTRcoreCorporate Power Purchase Agreement (PPA) for renewable energy from Murley Wind Farm. Agreement increased clean electricity supply from just under 50% to just under 70% of wind farm output to support Almac's expanded operations at Craigavon headquarters.
- Formosa PharmaceuticalscoreGlobal licensing agreement for development and commercialisation of ALM-401, a first-in-class EGFRxROR1 bispecific antibody-drug conjugate. Almac Discovery will collaborate on preclinical development while Formosa leads clinical development and commercialization.
- AstraZenecacoreCompanion diagnostics collaboration across multiple chronic disease indications including respiratory, cardiovascular, and metabolic diseases. Strategic partnership for biomarker-driven clinical trials.
- Future Medicines InstituteminorKey partnership announced for biomarker and diagnostic collaboration in support of precision medicine development programs.
- EORTC (European Organisation for Research and Treatment of Cancer)minorCollaboration established for tumour molecular profiling to support clinical trial programs and precision medicine initiatives.
Scale indicators10 records
Recent moves12 records
Expansion highlights7 records
Almac Group competitors and assessment
Company assessmentDirect peers
- Samsung Biologics: Korea-based CDMO specializing in large-scale biologics manufacturing, with growing exposure to gene therapy and ADC modalities. Competes for outsourced advanced therapy manufacturing contracts that increasingly overlap with Almac's service portfolio.
- Lonza Group: Swiss-headquartered global CDMO offering integrated small molecule and biologics API, drug product, and cell & gene therapy services. Lonza is the closest scale and scope comparable to Almac, both serving top biopharma with end-to-end drug development and manufacturing solutions.
- WuXi AppTec (WuXi STA): China-headquartered CRDMO offering API manufacturing, formulation, and analytical services across small molecules and biologics. WuXi STA competes with Almac for global small-molecule CDMO work and is rapidly expanding capacity across modalities.
- Siegfried Holding: Swiss-headquartered CDMO focused on API and finished drug product manufacturing for global pharma. Comparable to Almac's API Services and Pharmaceutical Development divisions in scale and customer overlap.
- Recipharm: European CDMO offering API and drug product manufacturing, particularly in inhalation, sterile injectables, and oral solid dose. Direct competitor to Almac in small-molecule drug product and pharmaceutical development services.
- Catalent: US-based CDMO providing drug substance, drug product, clinical supply, and cell & gene therapy services. Catalent overlaps directly with Almac across formulation development, clinical trial supply, and biologics/oral dose manufacturing for global biopharma.
Emerging players
- Eurofins Scientific: Global bioanalytical and clinical testing services group with growing CDMO exposure. Comparable to Almac Diagnostic Services in clinical trial testing and central laboratory capabilities.
Broad incumbents
- Charles River Laboratories: US-headquartered CRO/CDMO providing discovery, safety assessment, and manufacturing services. Overlaps with Almac Discovery and Almac Sciences in early-stage drug development and biologics support.
- IQVIA: World's largest clinical research services and technology provider, with biotech-facing development and eClinical technology offerings. Competes with Almac Clinical Technologies in IRT, eCOA, and broader eClinical platform markets.
- Thermo Fisher Scientific (Patheon CDMO): Operates one of the world's largest CDMO networks via its Patheon business, offering API, oral solid dose, sterile fill-finish, and clinical trial services. A scaled, publicly listed incumbent competing head-to-head with Almac for global biopharma development contracts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Almac Group social profiles
Digital presenceAlmac Group compliance and trust
Trust signalCompliance16 records
Almac Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Almac Group leadership team
Management profileNumber of profiles
Profiles3 records
Almac Group subsidiaries and ownership
Company hierarchySubsidiaries7 records
Almac Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Almac Group M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Almac Group
What does Almac Group do?
Almac Group is a contract development and manufacturing organization (CDMO) providing integrated pharmaceutical services across the entire drug development lifecycle. It offers API development and manufacture, formulation development, clinical trial supply and packaging, commercial-scale manufacturing, and precision medicine companion diagnostics. The company serves global biopharmaceutical and biotechnology companies through seven business units operating from 18 facilities across Europe, North America, and Asia-Pacific.
Is Almac Group a public or private company?
Almac Group is a private company. It is classified as family owned and is currently operating.
When was Almac Group founded?
Almac Group was founded in 1970. It employs 5,001 to 10,000 people.
Where is Almac Group based?
Almac Group is headquartered in Craigavon, United Kingdom, in the Europe region.
How does Almac Group make money?
Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are diagnostic Services.
Who are Almac Group's main competitors?
Direct peers on record are Samsung Biologics, Lonza Group, WuXi AppTec (WuXi STA), Siegfried Holding, Recipharm and Catalent. Eurofins Scientific is listed as an emerging player. Broad incumbents are Charles River Laboratories, IQVIA and Thermo Fisher Scientific (Patheon CDMO).
Does Almac Group have an API?
No public API is recorded for Almac Group.
What industry is Almac Group in?
Almac Group's product category is Pharmaceutical Contract Development and Manufacturing (CDMO) Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 2834.